Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COGT NASDAQ:LNTH NASDAQ:SRRK NYSE:TRLV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOGTCogent Biosciences$39.58-1.1%$34.81$9.25▼$43.73$6.76B0.342.27 million shs2.35 million shsLNTHLantheus$106.16+2.7%$99.32$47.25▼$111.86$6.90B-0.06962,223 shs351,568 shsSRRKScholar Rock$55.84-1.3%$48.79$27.07▼$57.80$6.69B0.671.40 million shs462,790 shsTRLVTrulieve Cannabis$8.92-0.2%$0.00$4.00▼$13.28$1.72BN/A614,179 shs653,420 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOGTCogent Biosciences+1.45%+3.39%+28.98%+8.28%+327.91%LNTHLantheus+0.57%-6.79%+2.41%+29.21%+30.58%SRRKScholar Rock+2.17%+2.84%+27.67%+13.14%+59.41%TRLVTrulieve Cannabis+0.32%-10.05%+886,599,900.00%+886,599,900.00%+886,599,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOGTCogent Biosciences$39.58-1.1%$34.81$9.25▼$43.73$6.76B0.342.27 million shs2.35 million shsLNTHLantheus$106.16+2.7%$99.32$47.25▼$111.86$6.90B-0.06962,223 shs351,568 shsSRRKScholar Rock$55.84-1.3%$48.79$27.07▼$57.80$6.69B0.671.40 million shs462,790 shsTRLVTrulieve Cannabis$8.92-0.2%$0.00$4.00▼$13.28$1.72BN/A614,179 shs653,420 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOGTCogent Biosciences+1.45%+3.39%+28.98%+8.28%+327.91%LNTHLantheus+0.57%-6.79%+2.41%+29.21%+30.58%SRRKScholar Rock+2.17%+2.84%+27.67%+13.14%+59.41%TRLVTrulieve Cannabis+0.32%-10.05%+886,599,900.00%+886,599,900.00%+886,599,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOGTCogent Biosciences 2.86Moderate Buy$43.7312.24% UpsideLNTHLantheus 2.73Moderate Buy$101.86-3.88% DownsideSRRKScholar Rock 3.12Buy$56.001.32% UpsideTRLVTrulieve Cannabis 1.50ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest TRLV, COGT, LNTH, and SRRK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/29/2026LNTHLantheus Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$115.006/18/2026SRRKScholar Rock Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight6/18/2026TRLVTrulieve Cannabis Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold6/16/2026TRLVTrulieve Cannabis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell (D-)5/29/2026COGTCogent Biosciences WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$55.005/27/2026LNTHLantheus MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$100.00 ➝ $115.005/26/2026LNTHLantheus Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)5/11/2026LNTHLantheus Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$98.00 ➝ $115.005/8/2026SRRKScholar Rock BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$53.00 ➝ $55.005/8/2026SRRKScholar Rock HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$58.00 ➝ $65.005/8/2026LNTHLantheus CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform(Data available from 7/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOGTCogent BiosciencesN/AN/AN/AN/A$3.84 per shareN/ALNTHLantheus$1.55B4.46$6.58 per share16.10$16.43 per share6.45SRRKScholar RockN/AN/AN/AN/A$2.41 per shareN/ATRLVTrulieve Cannabis$1.17B1.44N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOGTCogent Biosciences-$328.94M-$2.17N/AN/AN/AN/A-104.27%-54.64%8/4/2026 (Estimated)LNTHLantheus$233.56M$4.1525.5919.70N/A18.05%29.32%15.00%8/5/2026 (Estimated)SRRKScholar Rock-$377.94M-$3.59N/AN/AN/AN/A-163.52%-96.67%8/5/2026 (Estimated)TRLVTrulieve CannabisN/AN/AN/AN/AN/AN/AN/AN/AN/ALatest TRLV, COGT, LNTH, and SRRK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2026Q2 2026LNTHLantheus$1.30N/AN/AN/A$362.32 millionN/A8/5/2026Q2 2026SRRKScholar Rock-$0.84N/AN/AN/A$3.33 millionN/A8/4/2026Q2 2026COGTCogent Biosciences-$0.55N/AN/AN/A$0.00 millionN/A5/7/2026Q1 2026LNTHLantheus$1.25$1.46+$0.21$1.80$354.48 million$377.33 million5/7/2026Q1 2026SRRKScholar Rock-$0.82-$0.83-$0.01-$0.83$5.00 millionN/A5/5/2026Q1 2026COGTCogent Biosciences-$0.53-$0.53N/A-$0.53N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCOGTCogent BiosciencesN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/ATRLVTrulieve CannabisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOGTCogent Biosciences0.4115.1415.14LNTHLantheus0.472.832.64SRRKScholar Rock0.718.648.64TRLVTrulieve CannabisN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOGTCogent BiosciencesN/ALNTHLantheus99.06%SRRKScholar Rock91.08%TRLVTrulieve CannabisN/AInsider OwnershipCompanyInsider OwnershipCOGTCogent Biosciences6.59%LNTHLantheus1.70%SRRKScholar Rock13.30%TRLVTrulieve Cannabis3.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOGTCogent Biosciences80170.87 million159.61 millionOptionableLNTHLantheus1,19365.11 million64.00 millionOptionableSRRKScholar Rock140119.83 million103.89 millionOptionableTRLVTrulieve Cannabis9,000192.31 millionN/AN/ATRLV, COGT, LNTH, and SRRK HeadlinesRecent News About These CompaniesTrulieve targets September opening for 3 Texas MMJ storesJuly 7 at 10:59 PM | mjbizdaily.comMTrulieve Cannabis (NYSE:TRLV) Opens a New Market EraJuly 7 at 5:58 PM | kalkinemedia.comKTrulieve Cannabis Corp - Ordinary Shares (Sub Voting)July 7 at 12:58 PM | money.usnews.comMSOS Hits a 2026 High as Cannabis Stocks Brace for DEA's July 15 Rescheduling DeadlineJuly 3, 2026 | investorideas.comITrulieve Commemorates Georgia Medical Cannabis Launch with First SaleJuly 1, 2026 | prnewswire.comKim Rivers Sells 136,811 Shares of Trulieve Cannabis (NYSE:TRLV) StockJune 28, 2026 | americanbankingnews.comTrulieve CEO Sells $1.2 Million in Stock as Shares Jump 148% in One YearJune 27, 2026 | fool.comTrulieve Cannabis (NYSE:TRLV) CEO Sells 136,811 SharesJune 27, 2026 | insidertrades.comKim Rivers Sells 380,000 Shares of Trulieve Cannabis (NYSE:TRLV) StockJune 27, 2026 | americanbankingnews.comKim Rivers Sells 300,000 Shares of Trulieve Cannabis (NYSE:TRLV) StockJune 27, 2026 | americanbankingnews.comKim Rivers Sells 400,000 Shares of Trulieve Cannabis (NYSE:TRLV) StockJune 27, 2026 | americanbankingnews.comPromising Cannabis Stocks To Follow Today - June 26thJune 27, 2026 | americanbankingnews.comTrulieve Announces Planned Termination of Executive Automatic Securities Disposition PlanJune 26, 2026 | prnewswire.comTRLV PE / PEG RatioJune 26, 2026 | seekingalpha.comInsider Selling: Trulieve Cannabis (NYSE:TRLV) CEO Sells $2,451,000.00 in StockJune 26, 2026 | insidertrades.comTRLV Trulieve Cannabis Corp.June 24, 2026 | seekingalpha.comTrulieve Cannabis (NYSE:TRLV) CEO Sells $1,287,327.60 in StockJune 23, 2026 | insidertrades.comTrulieve Cannabis Corp. 2026 Q1 - Results - Earnings Call PresentationMay 7, 2026 | seekingalpha.comTrulieve Cannabis: Preparing For ReschedulingApril 22, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTRLV, COGT, LNTH, and SRRK Company DescriptionsCogent Biosciences NASDAQ:COGT$39.58 -0.43 (-1.07%) As of 03:40 PM Eastern This is a fair market value price provided by Massive. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Lantheus NASDAQ:LNTH$106.16 +2.75 (+2.66%) As of 03:40 PM Eastern This is a fair market value price provided by Massive. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Scholar Rock NASDAQ:SRRK$55.84 -0.72 (-1.27%) As of 03:40 PM Eastern This is a fair market value price provided by Massive. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.Trulieve Cannabis NYSE:TRLV$8.92 -0.01 (-0.16%) As of 03:39 PM Eastern This is a fair market value price provided by Massive. Learn more.Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, California, Massachusetts, Connecticut, Pennsylvania, and West Virginia, as well as directly to patients through home delivery. It produces approximately 550 stock keeping units, including flower, edibles, vaporizer cartridges, concentrates, topicals, capsules, tinctures, dissolvable powders, and nasal sprays. As of May 5, 2021, the company operated through 87 dispensaries in the United States. The company is headquartered in Quincy, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Exxon Could Be the Market's Next Big Comeback Stock Why Penguin Solutions May Be the Smartest AI Infrastructure Stock The Market Just Got Shaken—These 3 ETFs May Come Out Stronger Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns A Market Panic Just Discounted the AI Highway's Tollbooth Vertex’s Crinetics Deal Balances Growth with Integration Risk Apple and Broadcom Forge a Decade-Long Silicon Fortress These 3 Cash-Flow Stocks Give Investors More Than Just Growth Potential Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
